Biogen

Impact: Biogen announced compelling topline results from its Phase 2 CELIA study for diranersen, showing robust biomarker impact and cognitive benefit in early Alzheimer's disease, despite not meeting the primary endpoint for dose response. This positive data gives Biogen confidence to advance diranersen to registrational development.

Impact: Biogen is under investigation by Pomerantz LLP for alleged securities fraud after its stock price fell following the announcement of Phase 2 CELIA study results that missed its primary endpoint.

Impact: Biogen produces lecanemab (Leqembi), an anti-amyloid drug whose efficacy was challenged by the Cochrane review, which could negatively affect its market performance.

Impact: Biogen had an executive, Bharti Rai, recognized with an Ignite Leadership Award for driving enterprise-wide AI transformations within the company.

Impact: Biogen is a funding partner for the project, supporting the research into Alzheimer s disease biomarkers.

Impact: Biogen entered into a joint development and commercialization agreement for lecanemab with Eisai in 2014 and is involved in the AHEAD 3-45 clinical study.

Impact: Dr. Michelle Mellion previously held positions at Biogen, contributing to programs spanning remyelination.

Impact: Biogen>>> partly financed a phospho-tau vaccine program advanced by Declion Holdings LLC>>>.

Impact: Biogen, in collaboration with Eisai, developed Leqembi, one of the FDA-approved monoclonal antibody treatments for Alzheimer's Disease, which requires a positive beta-amyloid brain scan.